Apolipoprotein profile in type II diabetic patients with and without coronary heart disease

Barbagallo, Carlo M.; Averna, Maurizio; Amato, Salvatore; Marino, G.; Labisi, M; Rao, Angela Camemi; Barbagallo, Mario; Cupidi, G; Notarbartoló, A

doi:10.1007/bf02580943

Cited by 9 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were recently reported from other laboratories, showing, among other things, that the levels of plasma apoB, apoC-lll (40,41), and apoE (40) are higher in diabetic patients with vascular disease than in patients without vascular disease. It was, therefore, of considerable interest to determine the levels of apoB-containing lipoprotein families and their possible relationship to vascular disease.…”

Section: Discussionsupporting

confidence: 90%

Identification of ApoB-Containing Lipoprotein Families in NIDDM

et al. 1992

View full text Add to dashboard Cite

The purpose of this study was to determine the concentrations and composition of apoB-containing lipoprotein families in whole plasma and major lipoprotein density classes of a selected group of Native Americans from northeastern Oklahoma with non-insulin-dependent diabetes mellitus. The measurement of lipoprotein density classes showed that the total lipoprotein mass of very-low-density lipoproteins was significantly higher and that of high-density lipoproteins significantly lower in diabetic patients than nondiabetic control subjects regardless of their plasma triglyceride levels. The VLDLs were enriched with TG, free cholesterol, and apolipoproteins C-III and E. HDLs were enriched with TG but depleted of apoC-III and apoE. There was no change in the levels of TG-enriched low-density lipoproteins. Fractionation of VLDL by sequential immunoprecipitation with antisera to apoE and apoC-III established that increased concentrations of this density class in diabetic patients are due to elevated levels of TG-rich lipoprotein LP-B:C and lipoprotein LP-B:C:E. The levels of LP-B:C particles were increased more than the levels of LP-B:C:E particles. The LDLs were characterized by a slight increase in TG-enriched lipoprotein B and no change in the levels of LP-B:C and LP-B:C:E. There was no difference between diabetic patients with or without vascular disease in the levels of LP-B and LP-B:C:E. However, patients with vascular disease had higher concentrations of LP-B:C particles in VLDL and whole plasma than patients without vascular disease.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Discussionsupporting

confidence: 90%

Identification of ApoB-Containing Lipoprotein Families in NIDDM

et al. 1992

View full text Add to dashboard Cite

show abstract

“…Previous studies (5-9, [13][14][15] indicate that, in addition to LDL cholesterol level, this dyslipidemia is an important CVD risk factor in individuals with diabetes. Although the CVD risk associated with individual lipoproteins has been examined, it would be valuable to have a measure that reflects the combined risk of all lipoprotein changes observed in diabetes.…”

mentioning

confidence: 98%

Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes

et al. 2003

View full text Add to dashboard Cite

OBJECTIVE -To determine whether non-HDL cholesterol, a measure of total cholesterol minus HDL cholesterol, is a predictor of CVD in patients with diabetes. RESEARCH DESIGN AND METHODS -The Strong HeartStudy, a population-based study of CVD and its risk factors in 13 American Indian communities in three geographic areas in the U.S. The baseline examination, conducted between July 1989 and January 1992, consisted of a personal interview, a physical examination, and laboratory tests. Of the 4,549 women and men aged 45Ϫ74 years participating in the study, 2,108 had diabetes but no CVD at baseline. Data on fatal and nonfatal CVD were collected during the follow-up period through 31 December 1998 (average 9 years).RESULTS -Multivariable analyses indicated that non-HDL cholesterol is a strong predictor of CVD in men and women with diabetes and is particularly indicative of coronary events. Hazard ratios for the highest tertile of non-HDL cholesterol in men and women with diabetes (2.23 and 1.80, respectively) were higher than those for either LDL cholesterol or triglycerides alone in both men and women and were higher than the ratio of total/HDL cholesterol in women. The utility of non-HDL cholesterol in predicting CVD extended over a wide range of triglyceride concentrations.CONCLUSIONS -This study suggests that non-HDL cholesterol index may be particularly useful in predicting CVD risk in patients with diabetes. Diabetes Care 26:16 -23, 2003C ardiovascular disease (CVD) is currently the primary cause of morbidity and mortality in patients with diabetes (1-4). Because individuals with diabetes have greatly increased CVD risk compared with nondiabetic individuals (5-9), it is important to identify factors that may increase CVD risk in diabetic patients.In type 2 diabetes, there is a characteristic dyslipidemia consisting of elevated triglycerides, decreased HDL cholesterol, and LDL particles of altered composition (10 -12). Previous studies (5-9,13-15) indicate that, in addition to LDL cholesterol level, this dyslipidemia is an important CVD risk factor in individuals with diabetes. Although the CVD risk associated with individual lipoproteins has been examined, it would be valuable to have a measure that reflects the combined risk of all lipoprotein changes observed in diabetes. Some investigators (16 -18) have recently suggested that a measure of non-HDL cholesterol, which reflects total cholesterol minus HDL cholesterol (i.e., all apolipoprotein Bcontaining atherogenic lipoproteins), might be a useful marker of this combined risk. A recent study conducted in a cohort containing both diabetic and nondiabetic individuals showed that non-HDL cholesterol was a somewhat better predictor of CVD than LDL cholesterol (19). Furthermore, the Adult Treatment Panel (ATP-III) of the National Cholesterol Education Program has recommended using non-HDL cholesterol in assessing CVD risk in patients with diabetes (20). However, there have been no populationbased studies evaluating the utility of non-HDL cholesterol as a predictor of...

show abstract

“…It is the first study which investigates this correlation and we suggested a synergic action between MMPs and apolipoproteins in cardiovascular complications. In previous studies, Apo‐CIII and Apo‐E have been associated with a higher risk of diabetes 46 ; their blood levels were increased in chronic heart disease (CHD) in relation to dyslipoproteinaemia 47 and they were elevated in CAD 48 . High Apo‐CIII level was found in CAD patients, 49 as well as in patients with familial hyperlipidemia and cardiovascular disease 50 .…”

Section: Discussionmentioning

confidence: 91%

“…Apo-E have been associated with a higher risk of diabetes 46 ; their F I G U R E 4 Heatmap showing study biomarkers and the associated discrimination between patient and control groups blood levels were increased in chronic heart disease (CHD) in relation to dyslipoproteinaemia 47 and they were elevated in CAD. 48 High Apo-CIII level was found in CAD patients, 49 as well as in patients with familial hyperlipidemia and cardiovascular disease. 50 Apo-CII and Apo-E were higher in function of stenosis progression.…”

Section: Discussionmentioning

confidence: 99%

Identification of biomarker panels as predictors of severity in coronary artery disease

Braiek

Chahed

Dumont

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are implicated in atherosclerotic plaque rupture and recondition. Specific tissue inhibitors (TIMPs) control MMP functions. Both MMPs and TIMPs are potential biomarkers of plaque instability. Elevated Apo‐CII and CIII and Apo‐E levels are recognized as cardiovascular disease risk factors. We aimed to establish the best blood biomarker panel to evaluate the coronary artery disease (CAD) severity. Plasma levels of MMP‐3 and MMP‐9, TIMP‐1 and TIMP‐2, Apo‐CII, Apo‐CIII and Apo‐E were measured in 472 patients with CAD evaluated by coronary angiography and electrocardiography, and in 285 healthy controls. MMP‐3 and MMP‐9 plasma levels in CAD patients were significantly increased ( P < 0.001) compared to controls (3.54‐ and 3.81‐fold, respectively). Furthermore, these increments are modulated by CAD severity as well as for Apo‐CII and Apo‐CIII levels ( P < 0.001). TIMPs levels were decreased in CAD versus controls ( P < 0.001) and in inverse correlation to MMPs. Standard ROC curve approach showed the importance of panels of biomarkers, including MMP‐3, MMP‐9, TIMP‐1, TIMP‐2, Apo‐CII and Apo‐CIII, for disease aggravation diagnosis. A high area under curve (AUC) value (0.995) was reached for the association of MMP‐9, TIMP‐2 and Apo‐CIII. The unbalance between MMPs and TIMPs in vascular wall and dyslipidaemia creates favourable conditions for plaque disruption. Our study suggests that the combination of MMP‐9, TIMP‐2 and Apo‐CIII values (‘CAD aggravation panel’) characterizes the severity of CAD, that is electrophysiological state, number of involved vessels, stent disposal and type of stent.

show abstract

Apolipoprotein profile in type II diabetic patients with and without coronary heart disease

Cited by 9 publications

References 26 publications

Identification of ApoB-Containing Lipoprotein Families in NIDDM

Identification of ApoB-Containing Lipoprotein Families in NIDDM

Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes

Identification of biomarker panels as predictors of severity in coronary artery disease

Contact Info

Product

Resources

About